ClinicalTrials.gg
RecruitingNCT07387367ENOVIAUpdated Oct 19, 2026

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

A Phase 3 interventional study of cidofovir and Brincidofovir in Adenovirus Infections, sponsored by SymBio Pharmaceuticals. Recruiting at 81 sites in 13 countries. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by SymBio Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
2 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies in Adenoviridae Infections with a site in United States — 17 open to participants now, 21 under way, 2 of them phase 3. Adenoviridae Infections · United States.

Planned enrollment
12th of 68
180 · median 27
Started
2026
with 2 others
Phase 3
6 of 78
2 open now
Primary completion
2028-01
later than 9 of 18 live
Registered
77th of 78
by date
Lead sponsor
2 of 78
SymBio Pharmaceuticals

Among the 78 studies in Adenoviridae Infections with a site in United States, this one is the 12th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 9 of the 18 other live ones, and was the 77th registered.

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

Browse Adenoviridae Infections studies →

Open to participants now

17 of the 78 studies in Adenoviridae Infections with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Adenoviridae Infections studies recruiting now, 9 (36%) set no upper age limit and 12 (48%) stop at 75 or younger; 17 take children under 18; 4 take healthy volunteers.

This study: 2 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Adenoviridae Infections with a site in United States, or all of them as a file.
02

Study summary

This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized subjects are treated with either BCV or CDV until AdV viremia is confirmed as undetectable or until a maximum of 12 weeks of therapy, whichever occurs first. All subjects will be followed for a total of 24 weeks post-randomization, regardless of treatment assignment. Subjects will be assessed on a weekly basis through the end of treatment visit (EOT). Additional assessments will be performed at the test of cure (TOC) visit, which is 4 weeks after the last dose of study drug and at Weeks 12 and 24 post W1D1.

Read the detailed description

This Phase 3 multi-center, randomized, open-label study will assess efficacy of IV BCV, compared to IV CDV, in allo-HCT subjects with AdV viremia. Randomized subjects will be treated for up to a maximum of 12 weeks of therapy for both arms. Primary efficacy assessment will be performed at W5D1. Consistent with ECIL guidelines for high-risk patients, AdV viremia will be assessed weekly. Subjects randomized to receive BCV or CDV are treated until AdV DNA is confirmed to be undetectable in plasma for two consecutive tests 7 days apart, or until Week 12 post W1D1, whichever occurs first. Subjects will continue BCV or CDV as long as AdV viremia is detectable, contingent on tolerability, until viremia clears, or the subject reaches a maximum duration of 12 weeks of study drug treatment.

Subjects will receive assigned randomized therapy until time of AdV virological success plus 2 weeks, for up to a maximum of 12 weeks. All subjects will be followed through 24 weeks. All study visits and follow-up assessments must be completed regardless of the study drug treatment duration. All subjects are considered on study through the Week 24 follow-up visit.

For subjects who achieve virological success from their initial randomized study drug treatment and experience an AdV viremia recurrence, repeat treatment with their randomized study drug is allowed. There is no cross-over study drug treatment allowed in this study and subjects can only receive retreatment with their randomized study drug.

Subjects who stop study drug therapy due to confirmed undetectable AdV viremia may re-initiate study drug treatment if AdV viremia is subsequently confirmed at ≥ 1000 IU/mL by the designated central virology laboratory (recurrence). For the purposes of re-initiating study drug therapy, "confirmed viremia ≥ 1000 IU/mL" is defined as two consecutive results ≥ 1000 IU/mL from the designated central laboratory, with the second sample drawn at least 48 hours after the first sample.

Subjects who permanently discontinue study drug therapy for toxicity reasons are not eligible to re-initiate study drug dosing. Study procedures are to be followed during these Retreatment visits as applicable for BCV and CDV outlined in the schedule of assessments (SOA).

An independent Data Safety Monitoring Board (DSMB) will review accumulated safety data for this study when total combined enrollment in both arms is approximately 25% (45 subjects) and 50% (90 subjects). They will also review adverse events on an ongoing basis. They will make recommendations to the Sponsor based on review of these safety data. Further details regarding data safety monitoring guidelines will be included in the DSMB Charter. The DSMB will make determinations regarding continued enrolment and/or stopping the study for safety reasons.

An Endpoint Adjudication Committee (EAC) will be convened to evaluate baseline diagnosis and AdV disease clinical response as outlined in the EAC charter.

03

Conditions studied

  • Adenovirus Infections

Keywords

  • Brincidofovir
  • Cidofovir
  • Adenovirus
  • allo-HCT
  • BCV-PA02
  • ENOVIA
04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female, post-allo HCT within last 180 days, aged 2 months and older at time of signing form.
  2. Subject/Guardian willing and able to understand and provide written informed consent to participate in the study.
  3. In the investigator's judgement, the subject's clinical condition justifies treatment with IV BCV or IV CDV for AdV infection.
  4. Has adenoviremia, based on any of:

    • AdV viremia DNA ≥10,000 IU/mL, OR
    • Two consecutive and rising AdV viremia DNA results of ≥1,000 IU/mL at screening, OR
    • AdV viremia DNA of ≥1,000 IU/mL, AND

1. Lymphocyte count \<180/mm3, OR 2. Received T cell depletion, cord blood, or haploidentical transplant, OR 3. prior alemtuzumab, OR 4. anti-thymocyte globulin (ATG)

Exclusion criteria

Exclusion Criteria:

  1. Subject received an allo-HCT with a matched sibling donor
  2. Subject received more than 5 mg/kg of CDV for any reason in the 21 days prior to first dose of study drug.
  3. Subject is allergic or hypersensitive to IV BCV or IV CDV or any of their components.
  4. Subject received anti-AdV-specific cell-based therapy within 3 weeks prior to W1D1 or an anti-AdV vaccine at any time.
  5. Subject has participated in any other study within 30 days (or within 5.5 half-lives of the investigational product, whichever is longer) before signing the form (ICF), is currently participating in another interventional treatment trial with an investigational agent or is using an investigational device at the time of Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    IV BCV

    Drug: Brincidofovir

  • Active comparator
    IV CDV

    Drug: cidofovir

Interventions

  • CDV does not have a labeled indication for treating Adenovirus infection. CDV will be administered according to local guidelines and institutional standard of care practice.

    Also known as: IV CDV

  • Intravenous

    Also known as: SyB V-1901

06

What researchers measure

Primary outcomes

  1. To assess efficacy of intravenous (IV) brincidofovir (BCV), compared with IV cidofovir (CDV), in subjects after allo-HCT with adenovirus (AdV) viremia.

    The primary efficacy endpoint is defined as AdV virological success at W5D1. -Proportion of subjects with AdV virological success

    Time frame: Week (W) 5 Day (D) 1.

Secondary outcomes

  1. To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia.

    The proportion of subjects with overall success, as adjuducated by the EAC

    Time frame: Test Of Cure (Last Dose + 30 days)

  2. To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia.

    Incidence and severity of treatment-emergent adverse events (TEAEs).

    Time frame: Week 1 Day 1 Through End Of Study (Week 24).

  3. To assess the efficacy and safety of IV BCV, and IV CDV, in subjects after allo-HCT with AdV viremia.

    All cause mortality

    Time frame: Week 5 Day 1, Last Dose + 4 Days, Last Dose + 30 days, Week 12, and Week 24.

  4. BCV Plasma Concentrations will be collected, measured and reported

    The drug level (BCV) in plasma will be measured and used to examine the variability in drug concentrations among patients within the study population (i.e., population pharmacokinetics analysis).

    Time frame: Plasma samples will be collected at Week 1 Day 1, and Week 5 Day 1

07

Study locations

57 of 81 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jan 2028, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 4, 2026
StartActual
Mar 17, 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
22 sites changed recruiting status (22 now recruiting)
Show 22 sites
  • Stanford Medicine Children's Health · Palo Alto, United StatesNot yet recruiting→Recruiting
  • Rady Children's Hospital · San Diego, United StatesNot yet recruiting→Recruiting
  • Children's Hospital Colorado-Center for Cancer and Blood Disorders · Aurora, United StatesNot yet recruiting→Recruiting
  • University of Minnesota · Minneapolis, United StatesNot yet recruiting→Recruiting
  • Fred Hutchinson Cancer Center · Seattle, United StatesNot yet recruiting→Recruiting
  • University Health Network- Princess Margaret Cancer Centre · Toronto, CanadaNot yet recruiting→Recruiting
  • Hopital Maisonneuve-Rosemont - CIUSSS de l Est de L Ile de Montreal · Montreal, CanadaNot yet recruiting→Recruiting
  • Alberta Children's Hospital University of Calgary · Calgary, CanadaNot yet recruiting→Recruiting
  • Hopital Jeanne de Flandre · Lille, FranceNot yet recruiting→Recruiting
  • Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants · Nancy, FranceNot yet recruiting→Recruiting
  • Hôpital Saint-Louis · Paris, FranceNot yet recruiting→Recruiting
  • Necker Hospital · Paris, FranceNot yet recruiting→Recruiting
  • Charité University Hospital · Berlin, GermanyNot yet recruiting→Recruiting
  • University Medical Center Hamburg-Eppendorf (UKE) · Hamburg, GermanyNot yet recruiting→Recruiting
  • Medizinische Hochschule Hannover · Hanover, GermanyNot yet recruiting→Recruiting
  • University Children's Hospital · Münster, GermanyNot yet recruiting→Recruiting
  • Fondazione IRCCS Policlinico San Matteo · Pavia, ItalyNot yet recruiting→Recruiting
  • IRCCS San Raffaele Hospital · San Raffaele, ItalyNot yet recruiting→Recruiting
  • Vall d'Hebron University Hospital · Barcelona, SpainNot yet recruiting→Recruiting
  • Hospital Universitario de Salamanca · Salamanca, SpainNot yet recruiting→Recruiting
  • Great Ormond Street Hospital for Children · London, United KingdomNot yet recruiting→Recruiting
  • Royal Marsden Hospital · Sutton, United KingdomNot yet recruiting→Recruiting
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    22 sites changed recruiting status (22 now recruiting)
    Show 22 sites
    • Stanford Medicine Children's Health · Palo Alto, United StatesNot yet recruiting→Recruiting
    • Rady Children's Hospital · San Diego, United StatesNot yet recruiting→Recruiting
    • Children's Hospital Colorado-Center for Cancer and Blood Disorders · Aurora, United StatesNot yet recruiting→Recruiting
    • University of Minnesota · Minneapolis, United StatesNot yet recruiting→Recruiting
    • Fred Hutchinson Cancer Center · Seattle, United StatesNot yet recruiting→Recruiting
    • University Health Network- Princess Margaret Cancer Centre · Toronto, CanadaNot yet recruiting→Recruiting
    • Hopital Maisonneuve-Rosemont - CIUSSS de l Est de L Ile de Montreal · Montreal, CanadaNot yet recruiting→Recruiting
    • Alberta Children's Hospital University of Calgary · Calgary, CanadaNot yet recruiting→Recruiting
    • Hopital Jeanne de Flandre · Lille, FranceNot yet recruiting→Recruiting
    • Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants · Nancy, FranceNot yet recruiting→Recruiting
    • Hôpital Saint-Louis · Paris, FranceNot yet recruiting→Recruiting
    • Necker Hospital · Paris, FranceNot yet recruiting→Recruiting
    • Charité University Hospital · Berlin, GermanyNot yet recruiting→Recruiting
    • University Medical Center Hamburg-Eppendorf (UKE) · Hamburg, GermanyNot yet recruiting→Recruiting
    • Medizinische Hochschule Hannover · Hanover, GermanyNot yet recruiting→Recruiting
    • University Children's Hospital · Münster, GermanyNot yet recruiting→Recruiting
    • Fondazione IRCCS Policlinico San Matteo · Pavia, ItalyNot yet recruiting→Recruiting
    • IRCCS San Raffaele Hospital · San Raffaele, ItalyNot yet recruiting→Recruiting
    • Vall d'Hebron University Hospital · Barcelona, SpainNot yet recruiting→Recruiting
    • Hospital Universitario de Salamanca · Salamanca, SpainNot yet recruiting→Recruiting
    • Great Ormond Street Hospital for Children · London, United KingdomNot yet recruiting→Recruiting
    • Royal Marsden Hospital · Sutton, United KingdomNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07387367
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Mar 17, 2026
Primary completion
Jan 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Rochelle Maher
Contact
MedInfo@symbiopharma.com
+1-917-656-6951
Minori Rosales
study director · SymBio Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brincidofovir

Start the discussion